NCT00171899View on ClinicalTrials.gov

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

Unknown

Novartis Investigative Site, Toronto

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY